Hammerhead ribozymes in therapeutic target discovery and validation

Drug Discovery Today

Volumn 14, Issue 15-16, 2009, Pages 776-783

  Tedeschi, Lorena ^a   Lande, Caterina ^a   Cecchettini, Antonella ^b   Citti, Lorenzo ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CELL PROTEIN; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; HAMMERHEAD RIBOZYME; HYBRID PROTEIN; ONCOPROTEIN; SCLEROPROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SCREENING; DRUG TARGETING; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE FUNCTION; GENE SEQUENCE; GENE SILENCING; GENE TARGETING; GENE TECHNOLOGY; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; METABOLOMICS; NONHUMAN; PHENOTYPE; POINT MUTATION; PROTEOMICS; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; VALIDATION PROCESS; VIRUS GENE; VIRUS GENOME;

ANIMALS; DRUG DESIGN; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GENE TARGETING; HUMANS; RNA, CATALYTIC; RNA, SMALL INTERFERING; VALIDATION STUDIES AS TOPIC;

EID: 67651218978     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.05.003     Document Type: Review

References (60)

1. Kitano H. Systems biology: a brief overview. Science 295 (2002) 1662-1664
2. Noble D. Modeling the heart-from genes to cell to the whole organ. Science 295 (2002) 1678-1682
3. Scherer L., and Rossi J.J. Approaches for the sequence-specific knockdown of mRNA. Nat. Biotech. 21 (2003) 1457-1465
4. Bhindi R., et al. Brothers in arms. Am. J. Pathol. 171 (2007) 1079-1088
5. Buzayan J.M., et al. Non enzymatic cleavage and ligation of RNAs complementary to a plant virus satellite RNA. Nature 323 (1986) 349-353
6. Uhlenbeck O.C. A small catalytic oligoribonucleotide. Nature 328 (1987) 596-600
7. Ruffner D.E., et al. Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry 29 (1990) 10695-10702
8. Martick M., and Scott W.G. Tertiary contacts distant from the active site prime a ribozyme for catalysis. Cell 126 (2006) 309-320
9. Blount K.F., et al. The structure-function dilemma of the hammerhead ribozyme. Ann. Rev. Biophys. Biomol. Struct. 34 (2005) 415-440
10. Nelson J.A., and Uhlenbeck O.C. Minimal and extended hammerheads utilize a similar dynamic reaction mechanism for catalysis. RNA 14 (2008) 43-54
11. Citti L., and Rainaldi G. Synthetic hammerhead ribozymes as therapeutic tools to control disease genes. Curr. Gene Ther. 5 (2005) 11-24
12. Goodchild J. Hammerhead ribozymes for target validation. Expert Opin. Ther. Targets 6 (2002) 235-247
13. Lucier J.-F., et al. RiboSubstrates: a web application addressing the cleavage specificities of ribozymes in designed genomes. BMC Bioinf. 7 (2006) 480-488
14. Mercatanti A., et al. A method for prediction of accessible sites on an mRNA sequence for target selection of hammerhead ribozymes. J. Computat. Biol. 9 (2002) 641-653
15. Saksmerprome V., et al. Artificial motifs stabilize trans-cleaving hammerhead ribozymes under conditions of submillimolar divalent ions and high temperatures. RNA 10 (2004) 1916-1924
16. 15.1 changes the cleavage site specificity from NUH to NCH. Nucleic Acids Res. 26 (1998) 2279-2285
17. Kore A.R. Sequence specificity of the hammerhead ribozyme revisited: the NHH rule. Nucleic Acids Res. 26 (1998) 4116-4120
18. Scherr M., and Rossi J.J. Rapid determination and quantitation of the accessibility to native RNAs by antisense oligonucleotides in murine cell extracts. Nucleic Acids Res. 26 (1998) 5079-5085
19. Mir A.A., et al. Identifying ribozyme accessible sites using NUH triplet-targeting gapmers. Nucleic Acids Res. 29 (2001) 1906-1914
20. Pan W.-H., et al. A selection system for identifying accessible sites in target RNAs. RNA 7 (2001) 610-621
21. Lieber A., and Strauss M. Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Mol. Cell Biol. 15 (1995) 540-551
22. Citti L., et al. Quantitation of in vitro activity of synthetic trans-acting ribozymes. BioTechniques 23 (1997) 898-903
23. Thomson J.B., et al. The hammerhead ribozyme. In: Eckstein F., and Lilley D.M. (Eds). Catalytic RNA, Nucleic Acids and Molecular Biology vol. 10 (1996), Springer-Verlag, Berlin Heidelberg 173-196
24. Biegelman L., et al. Synthesis of 2'-modified nucleotides and their incorporation into hammerhead ribozymes. Nucleic Acids Res. 23 (1995) 4434-4442
25. Teng J., et al. DNA-RNA chimeric hammerhead ribozyme to transforming growth factor-β1 mRNA inhibits the exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats. Cardiovasc. Res. 48 (2000) 138-147
26. Kiessling R., et al. Cellular immunity to the Her-2/neu protooncogene. Adv. Cancer Res. 85 (2002) 101-144
27. Abounader R., et al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 16 (2002) 108-110
28. Santoro M., et al. Molecular mechanisms of RET activation in human cancer. Ann. NY Acad. Sci. USA 963 (2002) 116-121
29. Jiang S., et al. Preparation of anti-mouse caspase-12 mRNA hammerhead ribozyme and identification of its activity in vitro. World J. Gastroenterol. 11 (2005) 4094-4097
30. Nosrati M., and Kashani-Sabet M. Knockdown of telomerase RNA using hammerhead ribozymes and RNA interference. Methods Mol. Biol. 405 (2007) 113-131
31. Pennati M., et al. Ribozyme-mediated inhibition of surviving expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer. Oncogene 23 (2004) 386-394
32. Fei Q., et al. Experimental cancer gene therapy by multiple anti-survivin hammerhead ribozymes. Acta Biochim. Biophys. Sin. 40 (2008) 466-477
33. + cells to the alkylating antineoplstic drug. Cancer Gene Ther. 7 (2000) 905-909
34. Wu M., et al. Suppression of a DNA base excision repair gene, hOGG1, increases bleomycin sensitivity of human lung cancer cells. Toxicol. Appl. Pharmacol. 228 (2008) 395-402
35. Unwalla H., et al. Potent inhibition of HIV-1 gene expression and TAT-mediated apoptosis in human T cells by novel mono- and multitarget anti TAT/Rev/Env ribozymes and a general purpose RNA-cleaving DNA-enzyme. Antivir. Res. 72 (2006) 134-144
36. Weinberger M.S., et al. Effective anti-hepatitis B hammerhead ribozymes derived from multimeric precursors. Oligonucleotides 17 (2007) 104-112
37. Hu W.Y., et al. Adenovirus-mediated transfer of ribozyme targeting platelet-derived growth factor A-chain mRNA inhibits growth of vascular smooth muscle cells from spontaneous hypertensive rats. J. Cardiovasc. Pharmacol. 39 (2002) 858-865
38. val ribozyme. Acta Biochim. Pol. 53 (2006) 311-316
39. Grassi G., et al. Hammerhead ribozymes targeted against cyclin E and E2F1 cooperate to down-regulate coronary smooth muscle cell proliferation. J. Gene Med. 7 (2005) 1223-1234
40. Ye L., et al. Endogenous Bone Morphogenetic Protein-7 controls the motility of prostate cancer cells through regulation of Bone Morphogenetic Protein Antagonists. J. Urol. 178 (2007) 1086-1091
41. Yang J., et al. Systemic targeting Inhibitor of kB Kinase inhibits melanoma tumor growth. Cancer Res. 67 (2007) 3127-3134
42. Minoshima H., et al. Ribozyme and macroarray: identification of AP-2-regulated genes by macroarray profiling of gene expression. Genome Inform. 13 (2002) 290-292
43. Poliseno L., et al. Bcl-2 low-expressing MCF7 cells undergo necrosis rather than apoptosis upon staurosporine treatment. Biochem. J. 379 (2004) 823-832
44. Menon R.P., et al. Hammerhead ribozyme-mediated silencing of the mutant fibrillin-1 of tight skin mouse: insight into the functional role of mutant fibrillin-1. Exp. Cell Res. 312 (2006) 1463-1474
45. Musio A., et al. Inhibition of BUB1 results in genomic instability and anchorage-independent growth of normal human fibroblasts. Cancer Res. 63 (2003) 2855-2863
46. Tschuch C., et al. Off-target effects of siRNA specific for GFP. BMC Mol. Biol. 9 (2008) 9-60
47. Tang G. siRNA and miRNA: an insight into RISCs. Trends Biochem. Sci. 30 (2005) 106-114
48. Bushati N., and Cohen S.M. Micro RNA functions. Annu. Rev. Cell Dev. 23 (2007) 175-205
49. Jackson A.L., et al. Widespread siRNA 'off-target' trascript silencing mediated by seed region sequence complementarity. RNA 12 (2006) 1179-1187
50. Kashanisabet M., et al. Suppression of neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res. 54 (1994) 900-902
51. Phylactou L.A., et al. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target. Biochem. Biophys. Res. Commun. 249 (1998) 804-810
52. Hertel K.J., et al. Specificity of hammerhead ribozyme cleavage. EMBO J. 15 (1996) 3751-3757
53. Kawasaki H., and Taira K. A functional gene discovery in the Fas-mediated pathway to apoptosis by analysis of transiently expressed randomised hybrid-ribozyme libraries. Nucleic Acids Res. 30 (2002) 3609-3614
54. Wadhwa R., et al. Use of a randomized hybrid ribozyme library for identification of genes involved in muscle differentiation. J. Biol. Chem. 279 (2004) 51622-51629
55. Hovig E., et al. Optimization of hammerhead ribozymes for the cleavage of S100A4 (CAPL) mRNA. Antisense Nucleic Acids Drug Dev. 11 (2001) 67-75
56. Srivatsan S.G., and Famulok M. Functional nucleic acids in high throughput screening and drug discovery. Comb. Chem. High Throughput Screen. 10 (2007) 689-705
57. Kashani-Sabet M., et al. Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice. Proc.Natl. Acad. Sci. U.S.A. 99 (2002) 3878-3883
58. Kariko K., et al. Lipofectin-aided cell delivery of ribozyme targeted to human urokinase receptor mRNA. FEBS Lett. 352 (1994) 41-44
59. Dawson P.A., and Marini J.C. Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts. Nucleic Acids Res. 28 (2000) 4013-4020
60. Hertel K.J., et al. Numbering system for the hammerhead ribozyme. Nucleic Acids Res. 20 (1992) 3252